HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
190:@0.078769:0.033217:0.109813:0.033217:0.109813:0.013052:0.078769:0.013052:0.010348:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
is another important cause of visual loss in the elderly. :@0.076190:0.084931:0.485130:0.084931:0.485130:0.069149:0.076190:0.069149:0.003024:0.005866:0.005836:0.010326:0.009223:0.009903:0.005125:0.009207:0.009827:0.004551:0.005821:0.003024:0.014182:0.010311:0.009903:0.004551:0.005125:0.010326:0.009223:0.005125:0.005821:0.009782:0.010326:0.009192:0.005866:0.009827:0.005836:0.009903:0.004747:0.005836:0.008376:0.003024:0.005866:0.009192:0.010326:0.003024:0.005851:0.003024:0.009903:0.005866:0.005866:0.005836:0.003024:0.009223:0.005836:0.005125:0.009223:0.009827:0.005821:0.009827:0.003024:0.010357:0.009827:0.004551:0.003024:0.008104:0.004188:0.004188
With advanced disease, the patient has a microscopic :@0.076190:0.099040:0.485145:0.099040:0.485145:0.083257:0.076190:0.083257:0.014514:0.003024:0.005125:0.009223:0.004566:0.010326:0.010357:0.008376:0.010326:0.009223:0.009782:0.009827:0.010357:0.004581:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.004581:0.005125:0.009223:0.009827:0.004566:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.004581:0.009223:0.010326:0.005866:0.004581:0.010326:0.004581:0.014182:0.003024:0.009782:0.004551:0.009903:0.005866:0.009782:0.009903:0.010311:0.003024:0.009782:0.004188
residual field of vision, which ultimately will be lost en:@0.076190:0.113148:0.475938:0.113148:0.475938:0.097366:0.076190:0.097366:0.004551:0.009827:0.005866:0.003024:0.010357:0.009192:0.010326:0.003024:0.006138:0.003681:0.003681:0.009827:0.003024:0.010357:0.006138:0.009903:0.004747:0.006138:0.008376:0.003024:0.005866:0.003024:0.009903:0.009223:0.004188:0.006138:0.012564:0.009223:0.003024:0.009782:0.009223:0.006138:0.009192:0.003024:0.005125:0.003024:0.014182:0.010326:0.005125:0.009827:0.003024:0.008104:0.006138:0.012564:0.003024:0.003024:0.003024:0.006138:0.010311:0.009827:0.006138:0.003024:0.009903:0.005866:0.005125:0.006138:0.009827:0.009223
-:@0.475938:0.113148:0.480957:0.113148:0.480957:0.097366:0.475938:0.097366:0.005020
tirely if no treatment is received.:@0.076190:0.127257:0.309643:0.127257:0.309643:0.111474:0.076190:0.111474:0.005125:0.003024:0.004551:0.009827:0.003024:0.008104:0.004188:0.003024:0.004747:0.004188:0.009223:0.009903:0.004188:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.003024:0.005866:0.004188:0.004551:0.009827:0.009782:0.009827:0.003024:0.008376:0.009827:0.010357:0.004188
Treatment  of glaucoma is mostly with the daily  ad-:@0.090478:0.141365:0.480957:0.141365:0.480957:0.125583:0.090478:0.125583:0.006441:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.002616:0.009903:0.004747:0.006819:0.010175:0.003024:0.010326:0.009192:0.009782:0.009903:0.014182:0.010326:0.006819:0.003024:0.005866:0.006819:0.014182:0.009903:0.005866:0.005125:0.003024:0.008104:0.006819:0.012564:0.003024:0.005125:0.009223:0.006819:0.005125:0.009223:0.009827:0.006819:0.010357:0.010326:0.003024:0.003024:0.008104:0.004188:0.002646:0.010326:0.010357:0.005020
ministering of drops to lower IOp. since drops are very :@0.076190:0.155474:0.485115:0.155474:0.485115:0.139691:0.076190:0.139691:0.014182:0.003024:0.009223:0.003024:0.005866:0.005125:0.009827:0.004551:0.003024:0.009223:0.010175:0.005700:0.009903:0.004747:0.005700:0.010357:0.004551:0.009903:0.010311:0.005866:0.005700:0.005125:0.009903:0.005700:0.003024:0.009903:0.012564:0.009827:0.004551:0.005700:0.003417:0.013138:0.008950:0.004188:0.005730:0.007529:0.003024:0.009223:0.009782:0.009827:0.005700:0.010357:0.004551:0.009903:0.010311:0.005866:0.005700:0.010326:0.004551:0.009827:0.005700:0.008376:0.009827:0.004551:0.008104:0.004188
effective owing  to  improved newer  products  on  the :@0.076190:0.169582:0.485130:0.169582:0.485130:0.153800:0.076190:0.153800:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.007817:0.009903:0.012564:0.003024:0.009223:0.010175:0.004188:0.003613:0.005125:0.009903:0.004188:0.003613:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.010357:0.007817:0.009223:0.009827:0.012564:0.009827:0.004551:0.004188:0.003613:0.010311:0.004551:0.009903:0.010357:0.009192:0.009782:0.005125:0.005866:0.004188:0.003613:0.009903:0.009223:0.004188:0.003613:0.005125:0.009223:0.009827:0.004188
market, laser treatment or surgery is needed much less :@0.076190:0.183691:0.485130:0.183691:0.485130:0.167908:0.076190:0.167908:0.014182:0.010326:0.004551:0.007590:0.009827:0.005125:0.004188:0.005004:0.003024:0.010326:0.005866:0.009827:0.004551:0.005020:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.005004:0.009903:0.004551:0.005004:0.005866:0.009192:0.004551:0.010175:0.009827:0.004551:0.008104:0.005004:0.003024:0.005866:0.005020:0.009223:0.009827:0.009827:0.010357:0.009827:0.010357:0.005004:0.014182:0.009192:0.009782:0.009223:0.005004:0.003024:0.009827:0.005866:0.005866:0.004188
frequently today than in the past. Treatment has to be :@0.076190:0.197800:0.485115:0.197800:0.485115:0.182017:0.076190:0.182017:0.004747:0.004551:0.009827:0.010311:0.009192:0.009827:0.009223:0.005125:0.003024:0.008104:0.005065:0.005125:0.009903:0.010357:0.010326:0.008104:0.005080:0.005125:0.009223:0.010326:0.009223:0.005065:0.003024:0.009223:0.005080:0.005125:0.009223:0.009827:0.005065:0.010311:0.010326:0.005866:0.005125:0.004188:0.005080:0.006441:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.005065:0.009223:0.010326:0.005866:0.005080:0.005125:0.009903:0.005065:0.010311:0.009827:0.004188
continued for life. Elderly patients may have difficulty to :@0.076190:0.211908:0.485130:0.211908:0.485130:0.196125:0.076190:0.196125:0.009782:0.009903:0.009223:0.005125:0.003024:0.009223:0.009192:0.009827:0.010357:0.004143:0.004747:0.009903:0.004551:0.004143:0.003024:0.003024:0.004747:0.009827:0.004188:0.004143:0.008104:0.003024:0.010357:0.009827:0.004551:0.003024:0.008104:0.004158:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004143:0.014182:0.010326:0.008104:0.004143:0.009223:0.010326:0.008376:0.009827:0.004143:0.010357:0.003024:0.004747:0.003681:0.003681:0.009782:0.009192:0.003024:0.005125:0.008104:0.004143:0.005125:0.009903:0.004188
administer drops or remember to do so, and will need :@0.076190:0.226017:0.485115:0.226017:0.485115:0.210234:0.076190:0.210234:0.010326:0.010357:0.014182:0.003024:0.009223:0.003024:0.005866:0.005125:0.009827:0.004551:0.005624:0.010357:0.004551:0.009903:0.010311:0.005866:0.005609:0.009903:0.004551:0.005609:0.004551:0.009827:0.014182:0.009827:0.014182:0.010311:0.009827:0.004551:0.005609:0.005125:0.009903:0.005609:0.010357:0.009903:0.005609:0.005866:0.009903:0.004188:0.005609:0.010326:0.009223:0.010357:0.005609:0.012564:0.003024:0.003024:0.003024:0.005624:0.009223:0.009827:0.009827:0.010357:0.004188
help from family or friends.:@0.076190:0.240125:0.268353:0.240125:0.268353:0.224343:0.076190:0.224343:0.009223:0.009827:0.003024:0.010311:0.004188:0.004747:0.004551:0.009903:0.014182:0.004188:0.004747:0.010326:0.014182:0.003024:0.003024:0.008104:0.004188:0.009903:0.004551:0.004188:0.004747:0.004551:0.003024:0.009827:0.009223:0.010357:0.005866:0.004188
Visual acuity, IOp measurement, assessment of optic :@0.090478:0.254234:0.485130:0.254234:0.485130:0.238451:0.090478:0.238451:0.010614:0.003024:0.005866:0.009192:0.010326:0.003024:0.005352:0.010326:0.009782:0.009192:0.003024:0.005125:0.008104:0.004188:0.005352:0.003417:0.013138:0.008950:0.005352:0.014182:0.009827:0.010326:0.005866:0.009192:0.004551:0.009827:0.014182:0.009827:0.009223:0.005125:0.004188:0.005337:0.010326:0.005866:0.005866:0.009827:0.005866:0.005866:0.014182:0.009827:0.009223:0.005125:0.005352:0.009903:0.004747:0.005337:0.009903:0.010311:0.005125:0.003024:0.009782:0.004188
disc-cupping  and  visual  field  assessment  are  needed :@0.076190:0.268342:0.485145:0.268342:0.485145:0.252560:0.076190:0.252560:0.010357:0.003024:0.005866:0.009782:0.005020:0.009782:0.009192:0.010311:0.010311:0.003024:0.009223:0.010175:0.004188:0.002873:0.010326:0.009223:0.010357:0.004188:0.002857:0.008376:0.003024:0.005866:0.009192:0.010326:0.003024:0.004188:0.002873:0.003681:0.003681:0.009827:0.003024:0.010357:0.004188:0.002857:0.010326:0.005866:0.005866:0.009827:0.005866:0.005866:0.014182:0.009827:0.009223:0.005125:0.004188:0.002873:0.010326:0.004551:0.009827:0.004188:0.002857:0.009223:0.009827:0.009827:0.010357:0.009827:0.010357:0.004188
regularly to ensure the disease is optimally controlled, :@0.076190:0.282451:0.485145:0.282451:0.485145:0.266668:0.076190:0.266668:0.004551:0.009827:0.010175:0.009192:0.003024:0.010326:0.004551:0.003024:0.008104:0.006335:0.005125:0.009903:0.006335:0.009827:0.009223:0.005866:0.009192:0.004551:0.009827:0.006335:0.005125:0.009223:0.009827:0.006335:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.006350:0.003024:0.005866:0.006350:0.009903:0.010311:0.005125:0.003024:0.014182:0.010326:0.003024:0.003024:0.008104:0.006350:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.003024:0.009827:0.010357:0.004188:0.004188
and there is no further visual loss. Follow-up once stable :@0.076190:0.296559:0.485145:0.296559:0.485145:0.280777:0.076190:0.280777:0.010326:0.009223:0.010357:0.004324:0.005125:0.009223:0.009827:0.004551:0.009827:0.004324:0.003024:0.005866:0.004339:0.009223:0.009903:0.004324:0.004747:0.009192:0.004551:0.005125:0.009223:0.009827:0.004551:0.004309:0.008376:0.003024:0.005866:0.009192:0.010326:0.003024:0.004339:0.003024:0.009903:0.005866:0.005866:0.004188:0.004324:0.007333:0.009903:0.003024:0.003024:0.009903:0.012564:0.005020:0.009192:0.010311:0.004324:0.009903:0.009223:0.009782:0.009827:0.004324:0.005866:0.005125:0.010326:0.010311:0.003024:0.009827:0.004188
is usually once or twice a year.:@0.076190:0.310668:0.299771:0.310668:0.299771:0.294885:0.076190:0.294885:0.003024:0.005866:0.004188:0.009192:0.005866:0.009192:0.010326:0.003024:0.003024:0.008104:0.004188:0.009903:0.009223:0.009782:0.009827:0.004188:0.009903:0.004551:0.004188:0.005125:0.012564:0.003024:0.009782:0.009827:0.004188:0.010326:0.004188:0.008104:0.009827:0.010326:0.004551:0.004188
referenCes:@0.076190:0.343567:0.182628:0.343567:0.182628:0.323402:0.076190:0.323402:0.010718:0.009609:0.008870:0.009609:0.010718:0.009609:0.013674:0.014413:0.009609:0.009609
1. :@0.076190:0.355462:0.089220:0.355462:0.089220:0.343186:0.076190:0.343186:0.006515:0.003257:0.003257
Oduntan AO. prevalence and causes of low vision and blindness :@0.101390:0.355462:0.484213:0.355462:0.484213:0.343186:0.101390:0.343186:0.010219:0.008055:0.007150:0.007173:0.003986:0.008032:0.007173:0.004516:0.008702:0.010219:0.003257:0.004516:0.006961:0.003540:0.007644:0.006515:0.008032:0.002352:0.007644:0.007173:0.007608:0.007644:0.004516:0.008032:0.007173:0.008055:0.004516:0.007608:0.008032:0.007150:0.004563:0.007644:0.004563:0.004516:0.007702:0.003692:0.004516:0.002352:0.007702:0.009772:0.004516:0.006515:0.002352:0.004563:0.002352:0.007702:0.007173:0.004516:0.008032:0.007173:0.008055:0.004516:0.008020:0.002352:0.002352:0.007173:0.008055:0.007173:0.007644:0.004563:0.004563:0.003257
worldwide. :@0.101390:0.366363:0.167148:0.366363:0.167148:0.354088:0.101390:0.354088:0.009772:0.007702:0.003540:0.002352:0.008055:0.009772:0.002352:0.008055:0.007644:0.003257:0.003257
S Afr Optom.:@0.167148:0.366363:0.239667:0.366363:0.239667:0.354088:0.167148:0.354088:0.005856:0.003257:0.008702:0.003692:0.003540:0.003257:0.010219:0.008020:0.003986:0.007702:0.011030:0.003257
 2005;64:44-54.:@0.239656:0.366363:0.321735:0.366363:0.321735:0.354088:0.239656:0.354088:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
2. :@0.076190:0.377265:0.089220:0.377265:0.089220:0.364989:0.076190:0.364989:0.006515:0.003257:0.003257
Foster  A.  Vision 2020: The  cataract challenge. :@0.101390:0.377265:0.384071:0.377265:0.384071:0.364989:0.101390:0.364989:0.005703:0.007702:0.004563:0.003986:0.007644:0.003540:0.003257:0.003540:0.008702:0.003257:0.003257:0.003540:0.008255:0.002352:0.004563:0.002352:0.007702:0.007173:0.006809:0.006515:0.006515:0.006515:0.006515:0.003257:0.006809:0.005009:0.007173:0.007644:0.003257:0.003540:0.007608:0.008032:0.003986:0.008032:0.003540:0.008032:0.007608:0.003986:0.006809:0.007608:0.007173:0.008032:0.002352:0.002352:0.007644:0.007173:0.007914:0.007644:0.003257:0.003257
Community  Eye :@0.387611:0.377265:0.484201:0.377265:0.484201:0.364989:0.387611:0.364989:0.009560:0.007702:0.011030:0.011030:0.007150:0.007173:0.002352:0.003986:0.006303:0.003257:0.003540:0.006303:0.006303:0.007644:0.003257
Health. :@0.101390:0.388166:0.145123:0.388166:0.145123:0.375891:0.101390:0.375891:0.008032:0.007644:0.008032:0.002352:0.003986:0.007173:0.003257:0.003257
2000. 13:17-19.:@0.145123:0.388166:0.227203:0.388166:0.227203:0.375891:0.145123:0.375891:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
3. :@0.076190:0.399068:0.089220:0.399068:0.089220:0.386792:0.076190:0.386792:0.006515:0.003257:0.003257
Ambati J, Fowler BJ. Mechanisms of age-related macular degen-:@0.101390:0.399068:0.480967:0.399068:0.480967:0.386792:0.101390:0.386792:0.008702:0.011030:0.008020:0.008032:0.003986:0.002352:0.004374:0.005668:0.003257:0.004374:0.005703:0.007702:0.009772:0.002352:0.007644:0.003540:0.004363:0.006750:0.005668:0.003257:0.004374:0.010807:0.007644:0.007608:0.007173:0.008032:0.007173:0.002352:0.004563:0.011030:0.004563:0.004374:0.007702:0.003692:0.004374:0.008032:0.007914:0.007644:0.003904:0.003540:0.007644:0.002352:0.008032:0.003986:0.007644:0.008055:0.004374:0.011030:0.008032:0.007608:0.007150:0.002352:0.008032:0.003540:0.004374:0.008055:0.007644:0.007914:0.007644:0.007173:0.003904
eration. :@0.101390:0.409969:0.148333:0.409969:0.148333:0.397694:0.101390:0.397694:0.007644:0.003540:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257
Neuron.:@0.148322:0.409969:0.193489:0.409969:0.193489:0.397694:0.148322:0.397694:0.008702:0.007644:0.007150:0.003540:0.007702:0.007173:0.003257
 2012:75(1):26-39:@0.193477:0.409969:0.287492:0.409969:0.287492:0.397694:0.193477:0.397694:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.003904:0.006515:0.006515
4. :@0.076190:0.420870:0.089220:0.420870:0.089220:0.408595:0.076190:0.408595:0.006515:0.003257:0.003257
Jonas JB, Cheung CMG, panda-Jonas s. Updates on the epidemi-:@0.101390:0.420870:0.480932:0.420870:0.480932:0.408595:0.101390:0.408595:0.005668:0.007702:0.007173:0.008032:0.004563:0.003681:0.005668:0.006750:0.003257:0.003692:0.009560:0.007173:0.007644:0.007150:0.007173:0.007914:0.003681:0.009560:0.010807:0.010254:0.003257:0.003681:0.006961:0.008032:0.007173:0.008055:0.008032:0.003904:0.005668:0.007702:0.007173:0.008032:0.004563:0.003681:0.005856:0.003257:0.003681:0.007702:0.008020:0.008055:0.008032:0.003986:0.007644:0.004563:0.003692:0.007702:0.007173:0.003681:0.003986:0.007173:0.007644:0.003681:0.007644:0.008020:0.002352:0.008055:0.007644:0.011030:0.002352:0.003904
ology of age-related macular degeneration. :@0.101379:0.431772:0.364010:0.431772:0.364010:0.419497:0.101379:0.419497:0.007702:0.002352:0.007702:0.007914:0.006303:0.004351:0.007702:0.003692:0.004351:0.008032:0.007914:0.007644:0.003904:0.003540:0.007644:0.002352:0.008032:0.003986:0.007644:0.008055:0.004351:0.011030:0.008032:0.007608:0.007150:0.002352:0.008032:0.003540:0.004351:0.008055:0.007644:0.007914:0.007644:0.007173:0.007644:0.003540:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257
Asia Pac J Ophthal-:@0.365103:0.431772:0.480932:0.431772:0.480932:0.419497:0.365103:0.419497:0.008702:0.004563:0.002352:0.008032:0.004351:0.006961:0.008032:0.007608:0.004351:0.005668:0.004351:0.010219:0.008020:0.007173:0.003986:0.007173:0.008032:0.002352:0.003904
mol.:@0.101379:0.442673:0.125720:0.442673:0.125720:0.430398:0.101379:0.430398:0.011030:0.007702:0.002352:0.003257
 2017:6(6):493-497.:@0.125720:0.442673:0.229507:0.442673:0.229507:0.430398:0.125720:0.430398:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
5. :@0.076179:0.453575:0.089208:0.453575:0.089208:0.441299:0.076179:0.441299:0.006515:0.003257:0.003257
Karmel, M. Avastin new hopes and hesitations. :@0.101379:0.453575:0.378274:0.453575:0.378274:0.441299:0.101379:0.441299:0.006950:0.008032:0.003540:0.011030:0.007644:0.002352:0.003257:0.004951:0.010807:0.003257:0.004951:0.008702:0.006515:0.008032:0.004563:0.003986:0.002352:0.007173:0.004962:0.007173:0.007644:0.009772:0.004951:0.007173:0.007702:0.008020:0.007644:0.004563:0.004951:0.008032:0.007173:0.008055:0.004951:0.007173:0.007644:0.004563:0.002352:0.003986:0.008032:0.003986:0.002352:0.007702:0.007173:0.004563:0.003257:0.003257
Eyenet Magazine:@0.379991:0.453575:0.480944:0.453575:0.480944:0.441299:0.379991:0.441299:0.006303:0.006303:0.007644:0.007173:0.007644:0.003986:0.004951:0.010807:0.008032:0.007914:0.008032:0.004998:0.002352:0.007173:0.007644
 :@0.480944:0.453575:0.484201:0.453575:0.484201:0.441299:0.480944:0.441299:0.003257
2010:1:35-39:@0.101379:0.464476:0.170429:0.464476:0.170429:0.452201:0.101379:0.452201:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.003257:0.006515:0.006515:0.003904:0.006515:0.006515
6. :@0.076179:0.475378:0.089208:0.475378:0.089208:0.463102:0.076179:0.463102:0.006515:0.003257:0.003257
Quigley HA, Broman  AT.  The  number of people with glaucoma :@0.101379:0.475378:0.484189:0.475378:0.484189:0.463102:0.101379:0.463102:0.010242:0.007150:0.002352:0.007914:0.002352:0.007644:0.006303:0.006021:0.008032:0.008702:0.003257:0.006021:0.006750:0.003540:0.007702:0.011030:0.008032:0.007173:0.003257:0.002752:0.008702:0.005009:0.003257:0.003257:0.002752:0.005009:0.007173:0.007644:0.003257:0.002752:0.007173:0.007150:0.011030:0.008020:0.007644:0.003540:0.006021:0.007702:0.003692:0.006021:0.008020:0.007644:0.007702:0.008020:0.002352:0.007644:0.006021:0.009772:0.002352:0.003986:0.007173:0.006021:0.007914:0.002352:0.008032:0.007150:0.007608:0.007702:0.011030:0.008032:0.003257
worldwide in 2010 and 2020. :@0.101379:0.486279:0.265067:0.486279:0.265067:0.474004:0.101379:0.474004:0.009772:0.007702:0.003540:0.002352:0.008055:0.009772:0.002352:0.008055:0.007644:0.003257:0.002352:0.007173:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.008032:0.007173:0.008055:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
Br J Ophthalmol:@0.265079:0.486279:0.355590:0.486279:0.355590:0.474004:0.265079:0.474004:0.006750:0.003540:0.003257:0.005668:0.003257:0.010219:0.008020:0.007173:0.003986:0.007173:0.008032:0.002352:0.011030:0.007702:0.002352
. 2006:90:262-267.:@0.355590:0.486279:0.453956:0.486279:0.453956:0.474004:0.355590:0.474004:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
7. :@0.076179:0.497181:0.089208:0.497181:0.089208:0.484905:0.076179:0.484905:0.006515:0.003257:0.003257
Buhrmann RR, Quigley HA, Barron Y :@0.101379:0.497181:0.312787:0.497181:0.312787:0.484905:0.101379:0.484905:0.006750:0.007150:0.007173:0.003540:0.011030:0.008032:0.007173:0.007173:0.004986:0.007138:0.007138:0.003257:0.004986:0.010242:0.007150:0.002352:0.007914:0.002352:0.007644:0.006303:0.004998:0.008032:0.008702:0.003257:0.004986:0.006750:0.008032:0.003540:0.003540:0.007702:0.007173:0.004998:0.006961:0.003257
et al:@0.314527:0.497181:0.341538:0.497181:0.341538:0.484905:0.314527:0.484905:0.007644:0.003986:0.004998:0.008032:0.002352
. prevalence of glauco-:@0.341538:0.497181:0.480932:0.497181:0.480932:0.484905:0.341538:0.484905:0.003257:0.004998:0.006961:0.003540:0.007644:0.006515:0.008032:0.002352:0.007644:0.007173:0.007608:0.007644:0.004986:0.007702:0.003692:0.004986:0.007914:0.002352:0.008032:0.007150:0.007608:0.007702:0.003904
ma  in  a  rural  East African  population. :@0.101379:0.508082:0.327850:0.508082:0.327850:0.495807:0.101379:0.495807:0.011030:0.008032:0.003257:0.002117:0.002352:0.007173:0.003257:0.002117:0.008032:0.003257:0.002117:0.003540:0.007150:0.003540:0.008032:0.002352:0.003257:0.002117:0.006303:0.008032:0.004563:0.003986:0.005386:0.008702:0.003692:0.003540:0.002352:0.007608:0.008032:0.007173:0.003257:0.002117:0.008020:0.007702:0.008020:0.007150:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257
Invest  Ophthalmol  Vis Sci.:@0.329979:0.508082:0.480932:0.508082:0.480932:0.495807:0.329979:0.495807:0.002658:0.007173:0.006515:0.007644:0.004563:0.003986:0.003257:0.002117:0.010219:0.008020:0.007173:0.003986:0.007173:0.008032:0.002352:0.011030:0.007702:0.002352:0.003257:0.002117:0.008255:0.002352:0.004563:0.005386:0.005856:0.007608:0.002352:0.003257
 :@0.480932:0.508082:0.484189:0.508082:0.484189:0.495807:0.480932:0.495807:0.003257
2000:41:40-48:@0.101379:0.518984:0.176944:0.518984:0.176944:0.506708:0.101379:0.506708:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.003904:0.006515:0.006515